文献速递疼痛医学

射频消融与关节内间充质干细胞注射治疗膝骨关节炎:系统评价与网状Meta分析

Radiofrequency ablation versus intra-articular mesenchymal stem cell injection for knee osteoarthritis: a systematic review and network meta-analysis.
PubMed 文献 · Reg Anesth Pain Med · 2025-09-04

该系统评价与网状Meta分析纳入34项随机对照试验(n=2371),比较射频消融(RFA)与关节内间充质干细胞(IA MSC)治疗膝骨关节炎的疗效。结果显示,RFA和IA MSC在3个月和6个月疼痛管理上均显著优于常规治疗(中等确定性),RFA的SUCRA值最高;WOMAC评分方面,两者在3个月均显著改善,RFA在6个月仍保持领先,而MSC在6个月未显示显著优势。

要点

  • RFA与IA MSC在3个月和6个月疼痛管理上均显著优于常规治疗,证据确定性为中等。
  • RFA在疼痛缓解方面SUCRA值最高,提示其疗效可能最优。
  • WOMAC评分:两者3个月均显著改善,RFA在6个月仍领先,MSC在6个月无显著优势。

核心结论

  • RFA和IA MSC是膝骨关节炎有潜力的治疗选择,短期至中期疗效优于常规治疗,但证据确定性不一。

研究设计与样本

  • 系统评价与网状Meta分析,检索PubMed、MEDLINE、Embase、Cochrane Library、Web of Science并手工检索,纳入比较RFA或IA MSC与常规治疗的随机对照试验,共34项RCT(n=2371)。

主要发现

  • RFA和IA MSC在3个月和6个月疼痛管理上均显著优于常规治疗,证据确定性为中等。
  • RFA的SUCRA值最高,提示其在疼痛缓解方面疗效最优。
  • WOMAC评分:RFA和MSC在3个月均显著改善,RFA在6个月仍保持领先,MSC在6个月未显示显著优势。

临床怎么用

  • 对于膝骨关节炎患者,RFA和IA MSC可作为常规治疗疗效有限时的短期至中期治疗选择,RFA在疼痛缓解方面可能更具优势。

局限性

  • 研究存在异质性,且不同疗效结局的证据确定性水平不一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Knee osteoarthritis (OA) is a prevalent degenerative disease and causes disability, pain and imposes a substantial burden on patients. Conventional treatments for knee OA show limited effectiveness. Consequently, innovative treatments, such as radiofrequency ablation (RFA) and intra-articular mesenchymal stem cells (IA MSC), have gained attention for addressing these limitations. OBJECTIVE: We compared the efficacy of RFA and IA MSC for knee OA through a network meta-analysis (NMA). EVIDENCE REVIEW: A literature search was conducted using PubMed, MEDLINE, Embase, Cochrane Library, Web of Science and handsearching. Randomized controlled trials (RCTs) comparing RFA or IA MSC to conventional treatments for knee OA were included. The primary outcomes comprised the pain score and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). The clinical outcomes were compared using a frequentist approach, and the treatments were ranked using the surface under the cumulative ranking curve (SUCRA) values. FINDINGS: We included 34 RCTs (n=2371). Our NMA revealed that RFA and IA MSC were significantly more effective than conventional treatments in managing pain at both 3 and 6 months with moderate certainty. Specifically, RFA demonstrated the highest SUCRA values, indicating its superior efficacy. For WOMAC scores, both RFA and MSC showed significant improvements at 3 months, with RFA maintaining its lead at 6 months, although MSC did not display significant superiority at this stage. CONCLUSIONS: This analysis suggests that RFA and MSC are resilient treatment options in knee OA. Despite some study heterogeneity, these treatments consistently outperformed conventional treatments, particularly in the short to mid-term, although with varying levels of certainty in their efficacy. PROSPERO REGISTRATION NUMBER: CRD42023492299.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Park S, Park S, Jang JN, et al. Radiofrequency ablation versus intra-articular mesenchymal stem cell injection for knee osteoarthritis: a systematic review and network meta-analysis. Reg Anesth Pain Med. 2025. PMID: 38876799. doi:10.1136/rapm-2024-105526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。